Sarcoma News - LARVOL Sigma

Sarcoma	Welcome, Profile Billing Logout

«1 2...4 5 6 7 8910 11 12 13 14...1577 1578 »

|||||||||| Journal: Incidence and Predictors of Unexpected Malignancy in Benign Myomectomy or Hysterectomy. (Pubmed Central) - Sep 17, 2024
Conclusion Although this study demonstrated a low incidence of UM

|||||||||| Journal, Stroma: Unveiling a Jejunal Leiomyosarcoma Presenting as a Gastrointestinal Stromal Tumor: A Case Report. (Pubmed Central) - Sep 17, 2024
This case report emphasizes the importance of considering small bowel LMSs in the differential diagnosis of abdominal pain and highlights the challenges in diagnosing and treating these rare tumors. Early detection and appropriate management can improve the prognosis of patients with small bowel LMSs.

|||||||||| Journal: Stereotactic Ablative Radiation Therapy (SABR) for Adolescent and Young Adult Malignancies. (Pubmed Central) - Sep 17, 2024
SABR with BED10 ? 60 Gy resulted in durable LC for AYA patients, particularly those with sarcoma primaries, though poor outcomes were noted in metastatic CNS malignancies.

|||||||||| Journal: Comprehensive Management of Distal Clavicle Ewing's Sarcoma: A Case Highlighting Surgical Resection, Oncologic Challenges, and Rehabilitation Outcomes. (Pubmed Central) - Sep 17, 2024
The postoperative phase was marked by a comprehensive rehabilitation program, crucial for recovery and return to occupational activities. This case underscores the importance of early and accurate diagnosis, the effectiveness of a preoperative chemotherapy strategy, and the need for a multidisciplinary approach, including oncological treatment, surgical precision, and rehabilitative care.

|||||||||| Journal: An Unexpected Giant: A Case of Massive Paratesticular Extra-mammary Myofibroblastoma. (Pubmed Central) - Sep 17, 2024
This case underscores the importance of early and accurate diagnosis, the effectiveness of a preoperative chemotherapy strategy, and the need for a multidisciplinary approach, including oncological treatment, surgical precision, and rehabilitative care. A complete surgical excision was performed,

|||||||||| Journal, IO biomarker: A Unique Case of High-Grade Dedifferentiated Melanoma Without a Known Primary Site. (Pubmed Central) - Sep 17, 2024
By exploring the complexities of this multifaceted disease process, clinicians and researchers can gain valuable insights into potential areas for improved management strategies. Ultimately,

|||||||||| Journal: bio2Byte Tools deployment as a Python package and Galaxy tool to predict protein biophysical properties. (Pubmed Central) - Sep 17, 2024
This suite facilitates comprehensive assessments of protein characteristics, incorporating predictors for backbone and sidechain dynamics, local secondary structure propensities, early folding, long disorder, beta-sheet aggregation, and fused in sarcoma (FUS)-like phase separation. Our package significantly eases the integration and execution of these tools, enhancing accessibility for both computational and experimental researchers.

|||||||||| Journal: 3D chitosan/hydroxyapatite scaffolds containing mesoporous SiO2-HA particles: A new step to healing bone defects. (Pubmed Central) - Sep 17, 2024
Further, this scaffold's new bone formation percentage was equal to 90?% after 21?days post-surgery. Therefore, incorporating mesoporous SiO2-HA particles into CS/HA scaffolds can suggest a new future tissue engineering and regeneration strategy.

|||||||||| Journal: Discovery of a small-molecule inhibitor of KSHV lytic replication from the MMV Pandemic Response Box. (Pubmed Central) - Sep 17, 2024
MMV1645152 was identified as a promising inhibitor of KSHV lytic replication, suppressing KSHV immediate-early and late lytic gene expression and blocking the production of infectious KSHV virion particles at non-cytotoxic concentrations in cell line models of KSHV infection with or without EBV coinfection. MMV1645152 is a promising hit compound for the development of future therapeutic agents against KSHV-associated malignancies.

|||||||||| 5-fluorouracil / Generic mfg.
Journal: A thermoresponsive chitosan-based in situ gel formulation incorporated with 5-FU loaded nanoerythrosomes for fibrosarcoma local chemotherapy. (Pubmed Central) - Sep 17, 2024
After in vivo antitumor assessment in a subcutaneous autograft model, it was demonstrated that tumor growth inhibition in 14?days was 90?%. Therefore, the obtained injectable chitosan-based hydrogel containing 5-FU-loaded nanoerythrosomes illustrated promising potential as a candidate for local and enhanced delivery of chemotherapeutics at the tumor site.

|||||||||| Opdivo (nivolumab) / BMS, Cabometyx (cabozantinib tablet) / Exelixis
P1 data, Journal, Metastases: Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. (Pubmed Central) - Sep 17, 2024
P1
Supplementation with CBM588, a bifidogenic live bacterial product, has been associated with improved clinical outcomes in persons with metastatic renal cell carcinoma (mRCC) receiving nivolumab and ipilimumab...Our results provide a preliminary signal of improved clinical activity with CBM588 in treatment-naive participants with mRCC receiving cabozantinib and nivolumab. Further investigation is needed to confirm these findings and better characterize the underlying mechanism driving this effect.ClinicalTrials.gov identifier: NCT05122546.

|||||||||| Journal: 2022 (Pubmed Central) - Sep 17, 2024
It can only be sustained after having ruled out TFE3-rearranged RCC, TFEB-altered RCC, and FH-deficient RCC. For clinicians, the diagnosis of PRC implies suggesting an oncogenetic consultation to screen for an associated genetic tumor syndrome regardless of the patient's age.

|||||||||| Intra-Pericardial Chemotherapy for Pericardial Effusion in Soft Tissue Sarcoma of Lung: A Case Report (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1104;

|||||||||| A case of adult-onset malignant rhabdoid tumor of kidney responded to VAC therapy (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1100;

|||||||||| AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
Efficacy and Safety of Combined Radioactive Iodine-125 Seeds and PARP Inhibitor (Fluzoparib) in Advanced Unresectable Soft Tissue Sarcoma: A Phase II Trial (NCT05894018) (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1086;
P2

|||||||||| Multidisciplinary treatment of inguinoescrotal sarcomas. Analysis of results from 39 cases treated by surgical approach (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1046;

|||||||||| Epithelioid sarcoma: A retrospective study of efficacy and safety of first-line treatment (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1045;

|||||||||| Infantile versus adult-type fibrosarcoma and the risk of multiple primary malignancies (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1044;

|||||||||| Clinicopathological features and treatment outcomes of adolescents and adults Rhabdomyosarcoma: A single institutional experience. (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1043;

|||||||||| Age-adjusted trends of head and neck rhabdomyosarcoma (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1042;

|||||||||| Multimodal integration of radiology, pathology and transcriptomics for prediction of response to neoadjuvant therapy in patients with retroperitoneal liposarcoma (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1041;

|||||||||| Impact of adjuvant (AC)and neoadjuvant (NAC) chemotherapy in patients (pts) with soft tissue sarcoma (STS): a real-life exhaustive nationwide study (DEEPSARC). (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1039;

|||||||||| methotrexate / Generic mfg.
Chemotherapy without methotrexate in untreated localised osteosarcoma : a 10-year single center retrospective analysis. (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1038;

|||||||||| SBRT combined with PD-1 blockade for relapsed/ refractory osteosarcoma: a preliminary report (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1037;

|||||||||| cisplatin / Generic mfg., methotrexate / Generic mfg., doxorubicin hydrochloride / Generic mfg.
A comparison of the histopathological response of cisplatin- adriamycin- methotrexate versus cisplatin- adriamycin as a neoadjuvant chemotherapy in cases of primary non metastatic osteosarcoma in Indian population. (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1036;

|||||||||| 18F-FDG PET/CT can stratify the prognosis of standard responders after neoadjuvant chemotherapy in osteosarcoma. (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1035;

|||||||||| Osteosarcoma in Japan: Report from the Bone and Soft Tissue Tumor Registry 2006-2022 (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1034;

|||||||||| Pulmonary Resectable Mets of Osteosarcoma With Anti-angiogenic and CHemotherapy (PROACH), An open-label, single-arm phase 2 clinical trial: The pathological study of the post-surgical specimens (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1033;

|||||||||| Does Early childhood head and neck rhabdomyosarcoma increase the risk of second primary cancer? (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_886;

|||||||||| Analysis of cancer multigene panel testing for osteosarcoma using the Center for Cancer Genomics and Advanced Therapeutics database in Japan (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_807;

|||||||||| Jeselhy (pimitespib) / Otsuka
CHAPTER-GIST-101: A phase I study of pimitespib combined with imatinib in patients with imatinib-refractory gastrointestinal stromal tumor (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_612;

|||||||||| Qinlock (ripretinib) / Ono Pharma
Ripretinib Used for Preoperative Treatment of Metastatic Gastrointestinal Stromal Tumor After Failure of Imatinib Therapy (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_470;

|||||||||| Qinlock (ripretinib) / Ono Pharma
Study on monitoring ripretinib and its metabolites plasma concentration in Chinese patients with gastrointestinal stromal tumors (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_451;

|||||||||| Q&A and discussion (Hall 407) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_355;

|||||||||| Metastatic soft tissue sarcoma: Standard and new options (Hall 407) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_354;

|||||||||| Oligometastatic disease in STS: How to treat and when surgery is an option (Hall 407) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_353;

|||||||||| Neoadjuvant and adjuvant chemotherapy: When and how? (Hall 407) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_352;

|||||||||| Staging and prognostication (Hall 407) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_351;

|||||||||| Optimal treatment of soft tissue sarcomas (STS) (Hall 407) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_350;

|||||||||| Q&A and discussion (Hall 401) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_113;

|||||||||| Alveolar soft part sarcoma (ASPS) (Hall 401) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_112;

|||||||||| Chondrosarcoma (Hall 401) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_111;

|||||||||| Liposarcoma (Hall 401) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_110;

|||||||||| Desmoid tumours (Hall 401) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_109;

|||||||||| Focus on treatment of specific sarcoma types (Hall 401) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_108;

|||||||||| Qinlock (ripretinib) / Ono Pharma
Journal, Stroma, Metastases: Modern times call for modernized treatment strategies for advanced gastrointestinal stromal tumors. (Pubmed Central) - Sep 16, 2024
For clinicians, the diagnosis of PRC implies suggesting an oncogenetic consultation to screen for an associated genetic tumor syndrome regardless of the patient's age. No abstract available

|||||||||| Biomarker, Journal: Sarcomatoid change in combined hepatocellular carcinoma and cholangiocarcinoma as a poor prognostic factor. (Pubmed Central) - Sep 16, 2024
In the survival analysis, the sarcomatoid change group displayed a worse prognosis compared to the non-sarcomatoid change group {DFS: 4.0 [interquartile range (IQR): 1.2-6.8] vs. 23.0 (IQR: 9.3-36.7) months, P=0.001; OS: 19.0 (IQR: 7.2-30.8) vs. 85.0 (IQR: 31.8-138.2) months, P=0.004}. Sarcomatoid change is a poor prognostic factor for resected cHCC-CC.

|||||||||| Journal: PLK1 and its role in the evolving landscape of KRAS-mutated colorectal cancer. (Pubmed Central) - Sep 16, 2024
Sarcomatoid change is a poor prognostic factor for resected cHCC-CC. No abstract available

|||||||||| Journal: COL12A1 Promotes Osteosarcoma Progression via the FAK/PI3K/AKT/mTOR Pathway. (Pubmed Central) - Sep 16, 2024
No abstract available Our findings indicated that COL12A1 enhanced OS development by activating the FAK/PI3K/AKT/mTOR pathway, suggesting that COL12A1 could serve as a valuable biomarker for the prediction and identification of OS patients.

|||||||||| Retrospective data, Journal: The impact of margins and re-resection in pediatric synovial sarcoma. (Pubmed Central) - Sep 16, 2024
Second, our study extends this finding to report negative margins on initial resection or re-resection is associated with better OS/EFS than positive margins on initial resection or re-resection. Lastly, we found that there is no difference in outcomes associated with re-resection or <5?mm margins for R0 patients, indicating that re-resection and?<5?mm margins are acceptable if microscopic disease is removed.



	Diseases Companies Products Productz Mechanisms of Action Sites